{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T11:44:42Z","timestamp":1706010282430},"reference-count":9,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,5]]},"DOI":"10.1097\/wnf.0b013e318290cd41","type":"journal-article","created":{"date-parts":[[2013,5,11]],"date-time":"2013-05-11T12:43:51Z","timestamp":1368276231000},"page":"92-93","source":"Crossref","is-referenced-by-count":19,"title":["Tardive Dyskinesia Caused by Tetrabenazine"],"prefix":"10.1097","volume":"36","author":[{"given":"Peter A.","family":"LeWitt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-4-20210203","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjopharm.2010.08.006","article-title":"Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.","volume":"8","author":"Guay","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"key":"R2-4-20210203","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.","volume":"11","author":"Jankovic","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"R3-4-20210203","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1016\/j.clinthera.2012.06.010","article-title":"Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.","volume":"34","author":"Chen","year":"2012","journal-title":"Clin Ther"},{"key":"R4-4-20210203","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1002\/ana.410170217","article-title":"Tetrabenazine induces acute dystonic reactions.","volume":"17","author":"Burke","year":"1985","journal-title":"Ann Neurol"},{"key":"R5-4-20210203","first-page":"187","article-title":"Early course of new-onset tardive dyskinesia in older patients.","volume":"30","author":"Lacro","year":"1994","journal-title":"Psychopharmacol Bull"},{"key":"R6-4-20210203","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.410120308","article-title":"Tetrabenazine has properties of a dopamine receptor antagonist.","volume":"12","author":"Login","year":"1982","journal-title":"Ann Neurol"},{"key":"R7-4-20210203","first-page":"515","article-title":"Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain.","volume":"225","author":"Reches","year":"1983","journal-title":"J Pharmacol Exp Ther"},{"key":"R8-4-20210203","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1055\/s-2006-951608","article-title":"Dyskinesia during treatment with duloxetine.","volume":"39","author":"Deuschle","year":"2006","journal-title":"Pharmacopsychiatry"},{"key":"R9-4-20210203","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1002\/mds.25107","article-title":"Tardive dyskinesia is caused by maladaptive synaptic plasticity: a hypothesis.","volume":"27","author":"Teo","year":"2012","journal-title":"Mov Disord"}],"container-title":["Clinical Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/WNF.0b013e318290cd41","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T07:15:24Z","timestamp":1620976524000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002826-201305000-00004"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5]]},"references-count":9,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/wnf.0b013e318290cd41","relation":{},"ISSN":["0362-5664"],"issn-type":[{"value":"0362-5664","type":"print"}],"subject":[],"published":{"date-parts":[[2013,5]]}}}